MEDISYNERGICS, LLC

Biotech · Private

Small molecule therapeutic candidates for Human African Trypanosomiasis (sleeping sickness), targeting both Stage 1 and Stage 2 infections

medisynergics.com →
Grants
$1.2M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Novel Trypanocidal Compounds for the Treatment of Stage 1 and 2 HAT.$299,998
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Novel Trypanocidal Compounds for the Treatment of Stage and HAT$599,995
Federal grantDepartment of Health and Human Services · Phase I · Novel Trypanocidal Compounds for the Treatment of Stage 1 and 2 HAT.$299,997
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1292BIOORG3.14 LLC——
1293SUNOMIX THERAPEUTICS——
1294ImmunoTarget Therapeutics, Inc.——
1295MEDISYNERGICS, LLC——
1296COMPOVAX, LLC——
1297MEDIKINE INC——
1298NANGIOTX, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Kappa Opioid Receptor Compounds And Methods Of Using Sameapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.